These results confirm two new properties for TL-532, which showed proof-of-concept of inducing tumor cell death by apoptosis and reversing resistance to immune checkpoint inhibitors in previous studies.
Prof. Guido Kroemer’s team, from Gustave Roussy, will test Tollys’ specific TLR3 agonist, TL-532, to restore deficient chemotherapeutic responses in the context of FPR1 deficiency. FPR1 deficiency affects 30% of world population and is associated with precocious manifestation of breast, colorectal, esophageal, head and neck carcinomas.
ESMO – December 2021 – Presented by Dr Bettina Werle
OTS – September 2021 – Dr Marc Bonnin
OTS – September 2021 – Dr Sylvain Thierry
Recent Comments